BML Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

BML Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8M	Hold	3,167,231	–	–	6.91%	3
2025 Q4	$9.03M	Hold	3,167,231	–	–	7.8%	3
2025 Q3	$8.36M	Buy	3,167,231 +83,978	+3%	+$186K	7.66%	5
2025 Q2	$6.94M	Buy	3,083,253 +62,505	+2%	+$138K	5.25%	6
2025 Q1	$6.46M	Buy	3,020,748 +376,841	+14%	+$869K	5.23%	8
2024 Q4	$6.4M	Buy	2,643,907 +457,716	+21%	+$1.09M	3.97%	9
2024 Q3	$5.33M	Buy	2,186,191 +837,153	+62%	+$2.04M	3.14%	10
2024 Q2	$3.47M	Buy	1,349,038 +504,542	+60%	+$1.2M	2.47%	10
2024 Q1	$2.47M	Sell	844,496 -417,063	-33%	-$1.17M	1.63%	14
2023 Q4	$2.91M	Buy	1,261,559 +480,267	+61%	+$1.03M	2.21%	12
2023 Q3	$2.04M	Sell	781,292 -68,708	-8%	-$216K	1.87%	11
2023 Q2	$3.04M	Sell	850,000 -505,925	-37%	-$1.62M	2.74%	12
2023 Q1	$2.96M	Buy	+1,355,925	New	+$4.31M	2.56%	16

Other funds holding ORMP

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

BML Capital Management's ORMP Position: Q1 2026 in Review

BML Capital Management held its Oramed Pharmaceuticals (ORMP) position steady in Q1 2026 at 3,167,231 shares worth $10.8M. The position accounts for 6.91% of the portfolio, ranked #3.

BML Capital Management first reported a position in ORMP in Q1 2023 and has held it in 13 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

BML Capital Management held 3,167,231 shares of Oramed Pharmaceuticals worth $10.8M as of Q1 2026.
BML Capital Management left its Oramed Pharmaceuticals share count unchanged in Q1 2026.
Oramed Pharmaceuticals made up 6.91% of BML Capital Management's portfolio in Q1 2026, its #3 holding.
BML Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.